Liquidia Corporation (NASDAQ:LQDA - Get Free Report) insider Sarah Krepp sold 24,880 shares of the business's stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $70.28, for a total value of $1,748,566.40. Following the sale, the insider owned 121,863 shares of the company's stock, valued at approximately $8,564,531.64. The trade was a 16.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Sarah Krepp also recently made the following trade(s):
- On Monday, June 1st, Sarah Krepp sold 276 shares of Liquidia stock. The shares were sold at an average price of $60.87, for a total value of $16,800.12.
- On Monday, April 13th, Sarah Krepp sold 4,557 shares of Liquidia stock. The shares were sold at an average price of $38.37, for a total transaction of $174,852.09.
Liquidia Stock Up 0.8%
LQDA stock opened at $71.80 on Tuesday. The stock has a market cap of $6.39 billion, a P/E ratio of 512.89 and a beta of 0.57. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a twelve month low of $11.85 and a twelve month high of $72.71. The company's 50 day moving average is $50.54 and its two-hundred day moving average is $41.24.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million during the quarter, compared to analysts' expectations of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company's revenue was up 4187.1% on a year-over-year basis. Research analysts expect that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. purchased a new position in Liquidia during the fourth quarter worth about $25,000. Covestor Ltd lifted its position in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company's stock valued at $42,000 after purchasing an additional 359 shares during the period. Skandinaviska Enskilda Banken AB publ purchased a new stake in Liquidia in the 3rd quarter valued at approximately $30,000. FNY Investment Advisers LLC purchased a new stake in Liquidia in the 3rd quarter valued at approximately $34,000. Finally, NewEdge Advisors LLC acquired a new position in Liquidia during the 2nd quarter worth approximately $25,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
LQDA has been the subject of several research analyst reports. Zacks Research upgraded shares of Liquidia from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 5th. Wall Street Zen raised Liquidia from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 16th. Wells Fargo & Company upped their target price on Liquidia from $51.00 to $62.00 and gave the company an "overweight" rating in a research report on Tuesday, May 12th. Oppenheimer set a $75.00 price target on Liquidia in a research note on Friday, June 5th. Finally, HC Wainwright lifted their price target on Liquidia from $67.00 to $75.00 and gave the stock a "buy" rating in a research report on Friday, June 5th. Three equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $60.29.
Read Our Latest Research Report on LQDA
About Liquidia
(
Get Free Report)
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
